FIELD: medicine.
SUBSTANCE: invention represents a method for the inhibition of adipogenesis, which involves a stage, whereat adipocytes are placed into contact with an effective amount of Calebin-A.
EFFECT: extending the range of anti-obesity products.
14 cl, 3 ex, 3 tbl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CALEBIN A FOR HEPATIC STEATOSIS | 2015 |
|
RU2643297C2 |
| HEPATOPROTECTIVE ACTION OF GARCINOL | 2011 |
|
RU2585245C2 |
| KALEBIN A FOR TREATMENT OF OSTEOPOROSIS | 2016 |
|
RU2653103C2 |
| COMPOSITION CONTAINING SCIRPUSIN A AND SCIRPUSIN B, AND ITS POTENTIAL AS ANTIOBESITY AGENT | 2015 |
|
RU2691404C2 |
| COMPOSITIONS AND MULTI-PARAMETER ASSAYS FOR MEASURING BIOLOGICAL MEDIATORS OF PHYSIOLOGICAL HEALTH | 2007 |
|
RU2520080C2 |
| METHOD FOR DETERMINING PROBABILITY OF ISCHEMIC HEART DISEASE IN YOUNG PATIENTS WITH ABDOMINAL OBESITY | 2020 |
|
RU2749293C1 |
| METHOD FOR PREDICTING EXACERBATIONS OF BRONCHIAL ASTHMA FOR THE NEAR FIRST YEAR IN PATIENTS WITH CONCOMINANT OBESITY | 2018 |
|
RU2655829C1 |
| PROBIOTIC STRAIN OF BIFIDUS BACTERIA | 2010 |
|
RU2546251C2 |
| HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2581812C2 |
| BORON-BASED SMALL MOLECULES AS ANTI-INFLAMMATORY DRUGS | 2007 |
|
RU2508113C2 |
